DiagnoCure Inc. is a life sciences corporation that develops and commercializes high value cancer diagnostic test that increases clinician and patient confidence in making critical treatment decisions. The corporation has granted a worldwide exclusive license agreement to Gen Probe, now a wholly owned subsidiary of Hologic Inc. NASDAQ: HOLX operating as Hologic Gen Probe, for the development and commercialization of prostate cancer test using PCA , DiagnoCure s proprietary molecular biomarker. Gen Probe s PROGENSA R PCA test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Quote | Diagnocure Inc (OTCMKTS:DGCRF)
Last: | $1e-06 |
---|---|
Change Percent: | 0.0% |
Open: | $1e-06 |
Close: | $1e-06 |
High: | $1e-06 |
Low: | $1e-06 |
Volume: | 5,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Diagnocure Inc (OTCMKTS:DGCRF)
Message Board Posts | Diagnocure Inc (OTCMKTS:DGCRF)
Subject | By | Source | When |
---|---|---|---|
Emylers: DGCRF Financials 07/16/2014 20:12:18 DiagnoCure Inc. Period Ending Oct 31, 2013 Oct 31, 201 | Emylers | investorshangout | 07/17/2014 1:12:14 AM |
Stock_Tracker: Latest Diagnocure Inc (DGCRF) Headlines DiagnoCure announces fourth quarter 2013 and | Stock_Tracker | investorshangout | 03/09/2014 6:27:29 PM |
chartguy89: DGCRF 0.157 Stock Charts $DGCRF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 12:55:05 AM |
chartguy89: DGCRF Stock Charts Last: -0.0176 Tuesday, February 25, 2014 at 8:23:18 AM $DGCRF | chartguy89 | investorshangout | 02/25/2014 1:23:29 PM |
News, Short Squeeze, Breakout and More Instantly...